In 2013, we reported a pilot study on seven patients with another inherited optic neuropathy due to mitochondrial dysfunction, dominant optic atrophy (DOA) associated with OPA1 haploinsufficiency heterozygous mutations, who were treated for at least 1 year with idebenone.3 The gene discussed is OPA1; the disease is autosomal dominant optic atrophy.